CYB005

CYB005, or CYB-005, also known as deuterated phenethylamine derivative, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of psychiatric disorders and neuroinflammation.

Interactions

Pharmacology

Pharmacodynamics

CYB005 acts as a serotonin receptor agonist and is a serotonergic psychedelic. In addition, CYB005 may also inhibit serotonin and dopamine reuptake.

Chemistry

It is a phenethylamine derivative and a deuterated compound. The exact chemical structure of CYB005 does not yet seem to have been disclosed. However, it appears to be closely related to CYB210010, which itself is non-deuterated. In addition, CYB005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.

Development

As of October 2024, CYB005 is in the research or preclinical stage of development. It has been in this developmental stage since at least 2022. The drug is under development by Cybin. Other related drugs include the deuterated tryptamines CYB003 and CYB004.